Ipilimumab-induced autoimmune pancytopenia in a case of metastatic melanoma.

Pauline du Rusquec,M. Saint-Jean,A. Brocard,L. Peuvrel,A. Khammari,G. Quéreux,B. Dréno
DOI: https://doi.org/10.1097/CJI.0000000000000041
IF: 4.912
2014-07-01
Journal of Immunotherapy
Abstract:A 77-year-old patient treated with ipilimumab (anti-CTLA-4 antibody) for metastatic melanoma developed autoimmune pancytopenia (anemia, thrombocytopenia, and neutropenia) 8 days after the fourth infusion. This pancytopenia was resistant to high-dose oral corticosteroids (1 mg/kg) and to hematopoietic growth factors. It resolved after intravenous immunoglobulins injection. To date, only 1 case of autoimmune pancytopenia has been reported after this treatment. According to the case that we report, it seems essential to control the leukocyte count before any injection of ipilimumab.
What problem does this paper attempt to address?